Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 37 sources its claims cite is checked for support yet.
Abstract
BACKGROUND: Malaria, caused by Plasmodium falciparum and Plasmodium vivax, is commonly reported in Ethiopia. The World Health Organization (WHO) recommends treating P. vivax malaria with a schizonticidal drug and a 14-day course of primaquine (0.25-0.5 mg/kg body weight daily) to prevent relapses. In 2018, Ethiopia adopted a policy of primaquine radical cure (0.25 mg/kg for 14 days), with close monitoring for adverse events, but without prior glucose-6-phosphate dehydrogenase (G6PD) testing. This study aimed to assess the safety of this policy by monitoring the risk of haemolysis and other adverse events following the administration of primaquine. METHODS: A prospective observational study was conducted from May 2019 to June 30, 2021, enrolling patients with P. vivax and mixed malaria at four health centres. The clinics were chosen based on their P. vivax malaria patient volume and the expected prevalence of G6PD deficiency. Clinical, laboratory, and treatment data were gathered from patients at baseline and again on days 3, 7, 13, and 27. On day 13, all patients were evaluated for G6PD deficiency using the CareStart qualitative or SD Biosensor quantitative tests. RESULTS: A total of 879 patients were enrolled; none had G6PD deficiency. Among the 298 female patients tested with the SD Biosensor, 3 (1.0%) were found to have intermediate deficiency. On day three, the median fractional fall in haemoglobin was - 0.9% (range - 51.9-61.3). Nine patients had a drop in haemoglobin of more than 25% from baseline, of whom two patients had a haemoglobin level below 8 g/dL. On day 7, the median fractional drop was 0.8% (range - 51.9-48.3%). Five patients had a > 25% decline in haemoglobin between day three to day 7. None of the patients with the haemoglobin drop exhibited clinical symptoms attributable to haemolytic anaemia. By day 13, 91.9% of the patients had haematological recovery. No serious adverse events were reported. CONCLUSIONS: In this study, conducted in a population with a low prevalence of G6PD deficiency, a 14-day regimen of low-dose primaquine was well tolerated and resulted in few mild adverse events only. These findings support the current national policy for low-dose primaquine in Ethiopia without prior G6PD testing, if systems for monitoring adverse events are in place.
Overview
CoChat Summary
TL;DR
In a prospective observational study in Ethiopia, 879 patients with *P. vivax* or mixed malaria received chloroquine plus low-dose primaquine (0.25 mg/kg/day for 14 days) without prior G6PD testing; no G6PD-deficient patients were identified and no serious adverse events occurred. Low-dose primaquine was well tolerated with modest, mostly transient haemoglobin declines and 91.9% haematological recovery by day 13.
Key findings
- Among 879 analysed patients, none had G6PD deficiency; among 298 female patients tested with the SD Biosensor, 3 (1.0%) had intermediate deficiency.
- On day 3, the abstract reports a median fractional haemoglobin fall of −0.9% (range −51.9–61.3); 9 patients had a >25% haemoglobin drop, of whom 2 fell below 8 g/dL, all asymptomatic and completing the 14-day primaquine course. The results table reports mean haemoglobin decreased from 12.9 to 12.6 g/dL (mean absolute −0.3 g/dL; mean fractional −2.2%, SD 9.3).
- On day 7, the median fractional drop was 0.8% (range −51.9–48.3%); 5 patients had a >25% haemoglobin decline between days 3 and 7. By day 13, 91.9% (808/879) had haematological recovery.
- No serious adverse events were reported; 31 (3.5%) patients reported adverse events, all resolved without sequelae, and no participant recorded a urine colour score ≥5 (highest recorded score was 4).
Methods
- Prospective observational study conducted May 2019–30 June 2021 at four purposively selected health centres in Oromia, Amhara, and SNNP regions; enrolled patients with uncomplicated *P. vivax* or mixed malaria, age ≥6 months, excluding severe malaria, haemoglobin <8 g/dL, pregnancy/breastfeeding a child ≤6 months, prior haemolysis, and other criteria.
- Treatment was chloroquine (10 mg base/kg on days 0 and 1, 5 mg base/kg on day 2) plus primaquine 0.25 mg/kg/day for 14 days without prior G6PD testing; follow-up was on days 3, 7, 13, and 27, with haemoglobin by HemoCue, urine colour by Hillmen chart, G6PD by CareStart RDT or SD Biosensor on day 13/27, and adherence assessed by pill count.
- Data were double-entered into Epi Info version 3.5 and analysed in Stata version 14; analyses described demographic characteristics and absolute/percent haemoglobin changes between days 0–3, 3–7, and 0–13, minimum haemoglobin, >25% proportional decrease, and haemoglobin <8 g/dL.
Limitations
- Stated: no G6PD-deficient patients were enrolled, so the safety of low-dose primaquine in G6PD deficiency could not be assessed; there was no control group not administered primaquine, so haemoglobin changes cannot be attributed solely to primaquine; unmeasured confounders (nutritional deficiencies, haemoglobinopathies, baseline hydration, parasite density, recent/concurrent infections) were not assessed; recall and social desirability biases may affect adverse event and adherence reporting.
- Evident from the text: G6PD testing was performed on day 13 or 27, after primaquine exposure, not at baseline; the qualitative CareStart test detects <30% activity and may miss intermediate deficiency; the study used the low-dose 0.25 mg/kg regimen, so findings do not directly address higher WHO 2025 recommended doses; purposive site selection and exclusion of patients with haemoglobin <8 g/dL limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 34 Not checked · 72 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual and expected pill count were equal in more than 99% of the patients at all follow-up visits (Supplementary Table 1).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Adherence to treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these, two patients had haemoglobin levels fall below 8 g/dL.”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On day 3, nine patients had a fall in haemoglobin of more than 25%, and eight had a reduction of more than 3 g/dL (Table 4).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 627 patients tested using the Biosensor, the mean enzyme activity was 8.5 units per gram haemoglobin (U/g Hb) (Range: 4.2–17.5 U/g Hb) (Fig. 2).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > G6PD testing
plainn = 627- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By day 7, the mean haemoglobin was 12.9 g/dL (SD 1.7) (Table 3); this represents a mean absolute increase of 0.3 g/dL (SD 1.0) and a mean fractional rise of 2.8% (SD 8.8) from day 3 (Table 3).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 106 claims and to verify the 37 references still open.
- Probably not a substantial claim. 34
- It may state two separate claims as one. 33
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“| 13 | 13.0 (1.6) | 0.1 (0.01–0.8) | 0.8 (1.2) | 1.3 (9.8) |”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
Reported 0.8 · recomputed 0.1
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“In total, 31 (3.5%) patients reported a total of 315 clinical and laboratory adverse events (Table 5).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Adverse events
Reported 315 · recomputed 31
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Demographic and baseline characteristics
“| Mean Hb g/dL (± SD) | 12.9 [0.1] |”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
“| 0 | 12.9 (1.7) | | | |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Abstract > Results
“On day three, the median fractional fall in haemoglobin was − 0.9% (range − 51.9–61.3).”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
“| 6 | 1 | Male | 12.5 | 13.5 | 6.6 | 8.8 | 9.1 | 6.1 | 15.1 | – | − 6.9 | − 51.1 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
“One patient was a 3-year-old, G6PD normal (15.1 U/g Hb) male whose haemoglobin level dropped from 10.6 g/dL at baseline to 7.4 g/dL on day 3”
§ Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study > Results > Change in haemoglobin concentration during the follow-up period
“| 5 | 3 | Male | 16.6 | 10.6 | 7.4 | 10.0 | 10.9 | – | – | Normal | − 3.2 | − 30.2 | | 6 | 1 | Male | 12.5 | 13.5 | 6.6 | 8.8 | 9.1 | 6.1 | 15.1 | – | − 6.9 | − 51.1 |”
Citations
Cites
Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.
(1989) · Europe PMC (PubMed Central) · Cited by 500
TARLOV, A. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620140081013 · Cited by 273
Primaquine: the risks and the benefits
Ashley, E. A., Recht, J., & White, N. J. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-418 · Cited by 252
Recht, J., Ashley, E. A., & White, N. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006230 · Cited by 176
Douglas, N. M., Lampah, D. A., Kenangalem, E., Simpson, J. A., Poespoprodjo, J. R., Sugiarto, P., Anstey, N. M., & Price, R. N. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001575 · Cited by 131
Self-citationManagement of relapsing Plasmodium vivax malaria
Chu, C. S., & White, N. J. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1220304 · Cited by 130
8-Aminoquinoline Therapy for Latent Malaria
Baird, J. K. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00011-19 · Cited by 122
Prevalence of malaria infection in Butajira area, south-central Ethiopia
Woyessa, A., Deressa, W. A., Ali, A., & Lindtjørn, B. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-84 · Cited by 121
Douglas, N. M., Poespoprodjo, J. R., Patriani, D., Malloy, M. J., Kenangalem, E., Sugiarto, P., Simpson, J. A., Soenarto, Y., Anstey, N. M., & Price, R. N. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002379 · Cited by 107
Self-citation
Cited by
Still being checked.
Metadata
- Authors
- Shifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., Teka, H., Mumba, P., Murphy, M., Karmarkar, E., Price, R. N., Hwang, J., & Berhane, Y.
- Affiliations
- Addis Continental Institute of Public Health (ET)
- Addis Ababa University (ET)
- Federal Ministry of Health (ET)
- Tulane University (US)
- U.S. President's Malaria Initiative (US)
- Centers for Disease Control and Prevention (US)
- Mahidol University (TH)
- Corresponding author
- Shifraw, Tigest
- ORCID
- Venue
- Malaria Journal
- Published
- 2025-12-08
- Volume
- 25
- Issue
- 1
- Pages
- 27-27
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC12797556
- OpenAlex
- W4417102779
- Semantic Scholar
- cdc23cc11e5eb9a72b1c0b28122d05bc99a5f098
- Cited by
- 0
- References
- 26
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 35 d)
- Locations
- Malaria Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. President's Malaria Initiative
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- primaquine, Plasmodium vivax, radical cure, glucose-6-phosphate dehydrogenase deficiency, hemolysis, haemoglobin decline, drug safety, adverse drug reactions, malaria treatment, Ethiopia, haematological recovery, mixed malaria infection, public health facilities
- MeSH terms
- Adolescent, Adult, Aged, Antimalarials, Child, Child, Preschool, Ethiopia, Female, Glucosephosphate Dehydrogenase Deficiency, Health Facilities, Humans, Male, Middle Aged, Plasmodium vivax, Primaquine, Prospective Studies, Malaria, Vivax, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study. https://app.cochat.ai/papers/10.1186/s12936-025-05709-8
- The paper
- Shifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., Teka, H., Mumba, P., Murphy, M., Karmarkar, E., Price, R. N., Hwang, J., & Berhane, Y. (2025). Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study. Malaria Journal. https://doi.org/10.1186/s12936-025-05709-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.